+

WO2002076397A3 - Inhibiteurs de telomerase et leurs procedes d'utilisation - Google Patents

Inhibiteurs de telomerase et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2002076397A3
WO2002076397A3 PCT/US2002/009066 US0209066W WO02076397A3 WO 2002076397 A3 WO2002076397 A3 WO 2002076397A3 US 0209066 W US0209066 W US 0209066W WO 02076397 A3 WO02076397 A3 WO 02076397A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treatment
telomerase inhibitors
vivo
compositions
Prior art date
Application number
PCT/US2002/009066
Other languages
English (en)
Other versions
WO2002076397A2 (fr
Inventor
Richard L Tolman
Soya Gamsey
Shamal Mehta
Krisztina Pongracz
Original Assignee
Geron Corp
Richard L Tolman
Soya Gamsey
Shamal Mehta
Krisztina Pongracz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp, Richard L Tolman, Soya Gamsey, Shamal Mehta, Krisztina Pongracz filed Critical Geron Corp
Priority to AU2002306845A priority Critical patent/AU2002306845A1/en
Publication of WO2002076397A2 publication Critical patent/WO2002076397A2/fr
Publication of WO2002076397A3 publication Critical patent/WO2002076397A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés de xanthène et des compositions d'acridines, ainsi que des procédés d'inhibition de l'activité de la télomérase in vitro et de traitement d'états ou de pathologies induits par la télomérase ex vivo et in vivo. Les composés, les compositions et les procédés selon l'invention peuvent être utilisés seuls ou en combinaison avec d'autres agents pharmacologiquement actifs pour le traitement d'états ou de pathologies induits par l'activité de la télomérase, par exemple pour le traitement du cancer.
PCT/US2002/009066 2001-03-23 2002-03-21 Inhibiteurs de telomerase et leurs procedes d'utilisation WO2002076397A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002306845A AU2002306845A1 (en) 2001-03-23 2002-03-21 Telomerase inhibitors and methods of their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27854201P 2001-03-23 2001-03-23
US60/278,542 2001-03-23

Publications (2)

Publication Number Publication Date
WO2002076397A2 WO2002076397A2 (fr) 2002-10-03
WO2002076397A3 true WO2002076397A3 (fr) 2003-01-09

Family

ID=23065381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009066 WO2002076397A2 (fr) 2001-03-23 2002-03-21 Inhibiteurs de telomerase et leurs procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU2002306845A1 (fr)
WO (1) WO2002076397A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
EP1627025B1 (fr) 2003-05-09 2016-10-12 Applied Biosystems, LLC Materiaux polymeriques fluorescents contenant des colorants de rhodamine liposolubles
US7491830B2 (en) 2003-05-09 2009-02-17 Applied Biosystems Inc. Phenyl xanthene dyes
US9052324B2 (en) * 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
GB0505045D0 (en) * 2005-03-11 2005-04-20 Antisoma Plc Cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009212A1 (fr) * 1997-08-18 1999-02-25 Queen Mary & Westfield College Test de telomerase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009212A1 (fr) * 1997-08-18 1999-02-25 Queen Mary & Westfield College Test de telomerase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] POSSEL ET AL: "Dihydrodichlorofluorescein diacetate as fluorescent marker for peroxynitrite formation", XP002956452, accession no. STN Database accession no. 1997:712177 *
DATABASE HCAPLUS [online] READ ET AL: "Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors", XP002956453, accession no. STN Database accession no. 2001:327364 *
FEBS LETTERS, vol. 416, no. 2, 1997, pages 175 - 178, ISSN: 0014-5793 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 9, 2001, pages 4844 - 4849 *

Also Published As

Publication number Publication date
WO2002076397A2 (fr) 2002-10-03
AU2002306845A1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2002085299A3 (fr) Traitements therapeutiques recourant a l'application directe de compositions metalliques antimicrobiennes
WO2004062625A3 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
WO2004108713A8 (fr) Benzothiophenes substitutes par cycloalkyle et heterocycloalkyle, utiles comme agents therapeutiques
WO2004078712A3 (fr) Derives d'isoquinoline et leurs methodes d'utilisation
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2004030611A3 (fr) Inhibiteurs non nucleosidiques de transcriptases inverses
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
WO2005018545A3 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
WO2006052767A3 (fr) Compositions et methodes destinees a stabiliser des preparations medicamenteuses liposomales
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
EP2004637A1 (fr) Azines à noyau condensées et substituées et leur utilisation pour une thérapie anti-cancéreuse
WO2001078783A3 (fr) Compositions renfermant des agents naturels destinees au traitement du cancer
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
MXPA05013210A (es) Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
WO2003020280A3 (fr) Compositions et methodes de traitement du cancer
WO2004110990A3 (fr) Inhibiteurs de p38 et leurs methodes d'utilisation
WO2007010394A3 (fr) Inhibition du potentiel tumorigene de cellules souches tumorales par lif (facteur inhibiteur de la leucemie) et bmps (proteines morphogenetiques osseuses)
WO2003012051A8 (fr) Inhibiteur de methylation d'adn
WO2002030941A3 (fr) Inhibiteurs des topo-isomerases
WO2006034001A3 (fr) Procedes de traitement de l'infection par vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载